SEC Filings
Archer Aviation's Loss Widens To $274.6 Million As Testing And Development Costs Climb
Archer expects a larger adjusted loss next quarter as it prepares Midnight for Los Angeles flights and nears its Boeing deals.
SEC Filings
Archer expects a larger adjusted loss next quarter as it prepares Midnight for Los Angeles flights and nears its Boeing deals.
SEC Filings
Investment gains dominated quarterly profit, while lower legal bills helped narrow the adjusted loss.
SEC Filings
Maze expects its $477 million cash and investment balance to fund operations into 2029, with kidney drug results due in early 2027.
SEC Filings
The notes mature in February 2032 and allow early repayment if specified foreign ownership puts tax credits at material risk.
SEC Filings
The Anadarko tax dispute is already reserved, but losing would still require cash even without another tax charge beyond future interest.
SEC Filings
Global Atlantic increased its quarterly provision for expected commercial mortgage losses as its lending portfolio contracted.
SEC Filings
Helios construction commitments rose to $3.2 billion as Galaxy renewed its authorization to repurchase shares.
SEC Filings
The company expects $1.4749 billion in net proceeds from additions to bond series issued in September.
SEC Filings
Contract revenue of $1.7 million accompanied higher spending, while Rani expects its cash to fund operations at least through 2027.
SEC Filings
The former TESARO commercial chief oversaw ZEJULA's U.S. launch; Immuneering's lead cancer drug is still in clinical development.
SEC Filings
Davis previously ran InSightec and GE's MRI business; his Stryker board service is scheduled to begin January 1, 2027.
SEC Filings
Natalia Mirgorodskaya plans to leave November 30 to pursue another opportunity; Upstart will search for a permanent replacement.